logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Figure PDU-2. Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2002 to 2006 — last study available


Methods of estimation are abbreviated: CR=Capture-recapture; TM =Treatment multiplier; PM = Police multiplier; MI = Multivariate indicator; TP= Truncated Poisson; CM = Combined methods; MM= Mortality multiplier; OT= Other methods.

The symbol indicates a point estimate, a bar indicates an uncertainty interval, which can be either a 95 % confidence interval or an interval based on sensitivity analysis (see Table PDU-3).

Target groups may vary slightly owing to different methods and data sources; therefore comparisons should be made with caution.

* - Central estimate was calculated by doing a simple average of the Low and High estimate

1 - Estonia: Original age range of study was 15–44, rates have been adjusted to 15–64. Higher bound of estimation = 37.91 per 1 000 population.

2 - Finland: the original age range of study was 15–54.

Related links:

Statistical bulletin 2007: Figure PDU-2

For more details see Tables PDU-1 to PDU-3 in the Statistical bulletin 2008.

See also EMCDDA project (2003): National prevalence estimates of problem drug use in the European Union, 1995–2000, CT.00.RTX.23, EMCDDA, Lisbon, coordinated by the Institut für Therapieforschung, Munich.

See also ‘General notes for interpreting data’ on the Explanatory notes and help page


Reitox national focal points

(see the help page for information about formats etc.)

Page last updated: Thursday, 17 July 2008